Background: There is limited published scientific data on vaping recreational drugs other than cannabis. A recent review suggested that 15% of people vaping cannabis have also vaped a synthetic cannabinoid receptor agonist (SCRA) and identified over 300 Internet reports of e-liquid manufacture of recreational drugs and/or new psychoactive substances (NPS). Aim: To determine the prevalence of use of electronic vaping devices for recreational drug and NPS delivery in the UK. Design: A voluntary online survey using a convenience sample of UK adult participants (aged 16 years old and over) identified by a market research company. Methods: Data was collected regarding demographics, smoking history, electronic vaping device history and recreational drug/NPS use and route of administration. Results: There were 2501 respondents. The mean (6SD) age was 46.2 6 16.8 years old. The commonest lifetime recreational drug used was Cannabis (818, 32.7%). The majority of respondents had smoked (1545, 61.8%) with 731 (29.2%) being current smokers. The most commonly used SCRA product was 'Spice Gold' (173, 6.9%) and SCRA compound was ADB-CHMICA (48, 1.9%). 861 (34.4%) had used an electronic vaping device; 340 (13.6%) having used them for recreational drug administration; 236 (9.4%) reporting current use. The commonest lifetime recreational drug to be vaped was cannabis (155, 65.7%), with electronic cigarettes (230, 48.2%) being the commonest reported route of SCRA compound administration. Conclusion: 9.4% of respondents currently use electronic vaping devices for recreational drug administration with 6.2% reporting lifetime cannabis vaping use. Further larger scale studies are required to help inform the appropriate treatment and primary prevention strategies.
Introduction
Electronic cigarettes or 'E-cigarettes' have increased in popularity exponentially since their introduction in 2004. In the UK there was a rise from 700 000 users in 2012-2.6 million in 2015, with 19% of UK smokers reporting to have used them. 1 Studies in the United States showed that in 2015 e-cigarettes were the most commonly used 'nicotine-product' in adolescent groups with the greatest rate of uptake among high school (3.9%) and college (13.4%) students. 2 Newer generation modified e-cigarettes now vary widely from large portable tabletop vaporizers to smaller pen-style electronic nicotine delivery systems (ENDS) that are similar to e-cigarettes but contain larger reservoirs. The ability to regulate the evaporation temperature in newer devices facilitates the potential for their use to 'vape' an aerosolized mixture of water vapour and cannabis or, in theory, any psychoactive recreational drug or new psychoactive substance (NPS) that is heat stable. One recent review of drug user forums suggested that 15% of people vaping cannabis have also vaped a synthetic cannabinoid receptor agonist (SCRA) and identified over 300 Internet reports related to the manufacture and/or use of e-liquids containing recreational drugs and/or NPS including drugs such as cocaine, LSD, fentanyl and dimethyltryptamine. 3 Vaping of recreational drugs and NPS poses a serious potential public health risk due to: (i) the lack of robust data on risks associated with vaping recreational drugs/NPS; (ii) increasing availability, use and acceptance of vaping devices, especially amongst teens and young adults, which may lead to greater use of recreational drugs/NPS by this route thereby increasing overall drug exposure and (iii) the ability to vape deodorised drugs, especially cannabis, more discreetly with no smell (known as 'stealth vaping' 4 ) making drug use harder to detect and therefore prevent. Use of recreational and NPS drugs is common in the UK-in 2015/16 over one-third (35.0%) of UK adults aged 16-59 reported life-time use of recreational/illicit drugs. 5 It is important therefore to determine how common vaping is as a route of administration of these drugs in the UK. The aim of this study was to determine the prevalence of use of electronic vaping devices for recreational drug and NPS delivery in the UK.
Materials and methods

Study design
The study was a voluntary online survey using a convenience sample of adult participants (aged 16 years old and over). Participants were identified by Lightspeed GMI market research company using their survey panel of research respondents based in the UK. A standardized online questionnaire data collection form (available from the authors on request) was distributed via Lightspeed GMI to respondents who agreed to partake in the study in an e-mail invitation. The questionnaire was sent to participants in February 2017 and all respondents completed the online form within 7 days. Completed questionnaire responses were then tabulated and sent back to the study team. Ethical approval for the study was provided by the Research and Ethics Committee at King's College London (HR-16/17-3819) and the procedures were in accordance with the ethical standards.
Data collection
Demographic data were collected to determine the age, gender, region of the UK living in and highest educational attainment of participants. Data regarding smoking history and electronic vaping device use were also recorded. For electronic vaping device users data were collected on why they used a vaping device using pre-defined response categories of: 'My friends/family use them'; 'Out of interest'; 'Easier to get hold of than cigarettes'; 'Wanted to get high/a buzz'; 'Can do it indoors where you can't smoke'; 'Safer than cigarettes'; 'Less addictive than cigarettes'; 'To help me cut down the number of cigarettes smoked' and 'To help me stop smoking'. Electronic vaping device users were additionally asked about their previous/current use of these devices for recreational drug/'legal high' (i.e. NPS) administration with pre-specified products plus a free-text box for those products that had been used but were not listed. For respondents whom used electronic vaping devices for recreational drug/ 'legal high' use they were additionally asked why they chose this administration route using pre-defined response categories of: 'My friends do it'; 'Out of interest/curiosity'; 'Thought it was a safer way to take the drug I was offered it whilst out clubbing/ in a pub/at a party'; 'To be able to take the drug/'legal high' without being detected'; 'To be able to get drugs/'legal highs' into a bar/nightclub without it being found during a door search' and 'My partner/husband/wife does it'. For all respondents, data were collected on use of prespecified cannabis products and synthetic cannabinoid receptor agonists, use of Butane Hash Oil and commercial cannabidiol (CBD) vaping device products (specifically Kanavape and Cloud 9 products) and their respective effects compared to cannabis. Data was additionally collected on use of other common recreational drugs including cocaine powder, crack cocaine, ecstasy/ MDMA (3, 4-Methylenedioxymethamphetamine), GHB (Gamma Hydroxybutyrate), non-prescription amphetamine, heroin, ketamine and mephedrone.
To clarify terms in the questionnaire and subsequent analysis we stated that e-cigarettes resembled a conventional tobacco cigarette whereas ENDS resembled larger pen-style devices with interchangeable tank systems or modifications. The term 'electronic vaping device' is used to encompass e-cigarettes, ENDS and table-top vaporizers.
Results
Demographics
There were 2501 respondents. Of these 1294 (51.7%) were female. The mean (6SD) age was 46.2 6 16.8 years old (range 16-86). The highest educational levels attained were: GCSE (732, 29.3%), A level (729, 29.1%), degree (691, 27.6%), higher degree (260, 10.4%) and did not finish secondary school (89, 3.6%). Distribution of respondents within the UK showed the majority were from England [2119, 84.7% (with London alone 378, 15.1%)], then Scotland (207, 8.3%), Wales (123, 4.9%) and Northern Ireland (52, 2.1%).
Alcohol and recreational drug use
The majority (1179, 47.1%) of respondents consumed 1-7 units of alcohol a week, with 722 (28.9%) abstinent, 361 (14.4%) consuming 8-14 units, 138 (5.5%) consuming 15-21 units and 101 (4.0%) consuming over 22 units a week.
Reported lifetime use of recreational drugs showed the commonest drug used was Cannabis (818, 32.7%) followed by Nonprescription Amphetamine (270, 10.8%) and Cocaine Powder (267, 10.7%) ( Table 1) . Table 1 
Smoking
The majority of respondents had smoked at some point in their life (1545, 61.8%) with 731 (29.2%) being current smokers and 814 (32.6%) ex-smokers. The majority of respondents had never used an electronic vaping device (1640, 65.6%). The majority 819 (95.1%) had smoked cigarettes before using e-cigarettes or ENDS. 460 (53.4%) were currently using e-cigarettes, 78 (9.0%) currently use ENDS and 91 (10.6%) currently use both e-cigarettes and ENDS. 232 (26.9%) had used vaping devices in the past but currently do not use them.
The commonest reasons non-cigarette smokers gave for using an electronic vaping device was 'Out of interest' (24, 57.1%) and because they thought they were 'Safer than cigarettes' (23, 54.8%). Of the same group only 4 (9.5%) used them because they 'Wanted to get high/a buzz'. Of the group that currently smoke/previously smoked cigarettes the commonest reasons for using electronic vaping devices were 'To help cut down the number of cigarettes smoked' (685, 88.6%), 'To help stop smoking' (643, 83.2%) and because they thought they were 'Safer than cigarettes' (633, 81.9%). A greater proportion of this group used them because they 'Wanted to get high/a buzz' (207, 36.6%).
Vaping recreational drugs
Of the 861 (34.4%) that had used an electronic vaping device, over one third [340, 39.5% (13.6% of total respondents)] had used them for recreational drugs and 236 [27.4% (9.4% of total respondents)] reported currently using electronic vaping devices for recreational drug use. E-cigarettes (175, 74.2%) were the device used most frequently, followed by Table Top Vaporizer (48, 20.3%) and then ENDS (13, 5.5%). Of respondents who had never used an electronic vaping device for recreational drug use (2161, 86.4%), 623 (28.8%) were aware that these devices could be used for recreational drug use.
The commonest recreational drug to have been vaped was cannabis with 155 (65.7%) reporting lifetime use and 91 (38.6%) reporting use within the last 30 days. Lifetime use was also high for vaping MDMA/'ecstasy' (101, 42.8%), cocaine powder (94, 39.8%), mephedrone (73, 30.9%), crack cocaine (72, 30.5%), synthetic cannabinoid receptor agonists (67, 28.4%), fentanyl (63, 26.7%), heroin (61, 25.8%), alpha-PVP (alpha-pyrrolidinopentiophenone)(61, 25.8%), typtamines (60, 25.4%), NBOMe (2, 5-dimethoxy-4-bromophenethylamine) (59, 25%) and ketamine (58, 24.6%) (Figure 1 ). GHB (Gamma Hydroxybutyrate) (1, 0.4%), Magic Mushrooms (1, 0.4%), Solvents (1, 0.4%) and LSD (Lysergic acid diethylamide) (1, 0.4%) were also self-reported via free text entry to have been vaped by individual respondents.
As shown in Figure 2 , the commonest reasons given for using a vaping device to take recreational drugs were 'My friends do it' (143, 60.6%), 'Out of interest' (127, 53.8%) and 'Thought it was a safer way to take drugs' (110, 46.6%) (Figure 2 ).
Only 85 (36.0%) of respondents used them 'To be able to get drugs into a bar/nightclub without it being found during a door search'. 265 (10.6%) had heard of Butane Hash Oil and 92 (3.7%) had used it with 38 (42.2%) of these stating that its effects were better than cannabis. 216 (8.6%) had heard of Kannavape and 91 (3.6%) had used it with 40 (44.0%) of these stating that its effects were better than cannabis. 228 (9.1%) had heard of Cloud 9 and 81 (3.2%) had used it with 30 (37.0%) of these stating that its effects were better than cannabis.
The commonest reported cannabis product to be used was cannabis resin (409, 16.4%) with smoking it (373, 91.2%) the commonest route of use, followed by taking it orally (93, 22.7%), taking by electronic cigarette (26, 6.4%), Of the pre-specified Synthetic Cannabinoid Receptor Agonist (SCRA) products described, 'Spice' was the most widely heard of (1005, 40.2%), followed by 'Black Mamba' (785, 31.4%) and 'Spice Gold' (677, 27.1%) ( Table 3 ). The most commonly used synthetic cannabinoid products were 'Spice Gold' (173, 6.9%), 'Magic Gold' (152, 6.1%) and 'Exodus' (146, 5.8%) ( Table 3) . Summating the reported routes of administration the commonest was smoking (293, 31.6%), followed by oral (204, 22.3%), e-cigarette (177, 19.5%), table top vaporizer (154, 16.9%) and finally ENDS (93, 9.7%).
Of the pre-specified SCRA compounds described; AB-FUMINACA was the most widely heard of (129, 5.2%), followed by AM-2201 (122, 4.9%) and ADB-PINACA (118, 4.7%) ( Table 3) . The most commonly used SCRA compound was ADB-CHMICA (48, 1.9%). Compared to SCRA products, e-cigarette (230, 48.2%) was the commonest reported route of SCRA compound administration, followed by oral (189, 39.6%), smoking (158, 33.1%), table top vaporizer (91, 19.1%) and finally ENDS (80, 16.8%).
Discussion
In this study of 2501 respondents, we have demonstrated that a significant proportion (13.6%) report lifetime use of an electronic vaping device for recreational drug administration with 9.4% of respondents reporting current use. The overall reported lifetime use of electronic vaping devices was 34.4%. This is higher than 6 This may be partly explained by an increase in e-cigarette uptake by the date of this study but more likely is associated with our study respondents having a higher than national current smoking prevalence of 29.2% compared to the UK prevalence of 17.2%. 6 The overall prevalence of recreational drug use in our study was also higher, but comparable, across all drugs classes to those of the CSEW findings from 2015/16 5 ( Table 1 ); indicating that our cohort of reported recreational drug users are generalizable to the national average. Cannabis was the commonest recreational drug reported to be both used in general and vaped; with 32.7% of respondents reporting life-time cannabis use and 6.2% of all of those surveyed reporting lifetime cannabis vaping. These rates are similar to data from previous studies. In a 2015 survey of 3 847 students in five high schools in Connecticut, USA, 27.9% had used an e-cigarette; and 5.4% had vaped cannabis. 7 Another study in 2016 of 4 269 US adults aged 18 years or over reported a 9.9% life-time use of vaping cannabis and 7.6% past month use. 8 In selected groups of cannabis smokers previous studies have reported rates of ever vaping cannabis of up to 61% 9 whereas our study found 18.9% of life-time cannabis smokers had vaped cannabis as well. Cannabis resin was the most well heard of and most popular cannabis product used via all routes except for the table top-vaporizer for which hashish oil was the preferred product. Cannabis hashish oil is known to contain >60% THC (compared with 5-10% in cannabis herb/resin), and it may be due this more potent formulation that it is preferred for table top-vaporizer use which is predominantly used in groups rather than individually. 4 Over a quarter (28.8%) of those who did not report vaping of recreational drugs were aware of the potential route of use suggesting that there is awareness of vaping of recreational drugs amongst the wider public. Subgroup analysis showed that only 1.6% of the non-cigarette smoker respondents had used electronic vaping devices for recreational drug use. In contrast 21.0% of current/ex-smokers had used vaping devices for recreational drug use indicating that cigarette smoking may be a gateway to further recreational drug experimentation or viceversa. This notion is again reflected in the reasons respondents gave for using electronic vaping devices; with only 9.5% of noncigarette smokers reporting use of vaping because they 'Wanted to get high/a buzz' compared to 36.6% of the current/ex-smoker cohort.
Of concern was the high overall reported percentage of vaping other recreational drugs, with lifetime vaping high across all drug classes ( Figure 1 ). As mentioned, in a recent review of drug user forums approximately 15% of cannabis vapers reported that they had vaped SCRAs, 3 in our study vaping of SCRAs was more common (38.3%) in cannabis vapers. The subgroup analysis of reported cannabis vapers showed that they also made-up the vast majority [mean (6SD) of 88.6% 6 3.1%] of respondents whom vape other recreational drugs as well. Of note, on further analysis of the individual results the same cohort of 49 respondents made up the bulk of these positively reported users. Of reported SCRA use there is a clear difference between routes of administration for the SCRA products vs. the SCRA compounds; with smoking (31.6%) being favoured for SCRA products and electronic cigarettes (48.2%) being favoured for SCRA compounds. This difference may be due to the so called One major limitation of this study is that the recording of drug use is self-reported. This is evident in the same cohort of 49 respondents making up the majority of respondents whom report vaping drugs other than Cannabis, SCRAs, MDMA/ Ecstasy and Cocaine Powder. If we excluded this cohort of potential anomalous respondents we would still however have a substantial number of respondents (291, 11.6%) whom use electronic vaping devices for recreational drug use leading us to believe that the overall trend in use is still valid.
A second limitation in the use of Questionnaires is that respondents cannot ask clarifying questions. This may have been apparent in some misconception of the term 'Electronic Nicotine Devices (ENDS)' with respondents misidentifying them as 'Electronic Cigarettes' as they are colloquially better known.
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A clear text based distinction was made in the questionnaire but in future studies the use of pictorial examples would reduce any misunderstanding. Nevertheless, it was the global use of electronic vaping devices for recreational drug administration that was the main outcome being looked at, thus sub-group misidentification of electronic vaping device would not have altered the overall results obtained.
Conclusion
The limited published scientific data on vaping drugs other than cannabis means the prevalence is poorly understood. Further work is required to inform the appropriate treatment and primary prevention strategies for this emerging issue of a 'vaping culture' that includes the perceived positive attributes of vaping cannabis and the marketing of electronic vaping devices not just for nicotine use. 11 This novel culture could increase the prevalence of use; decrease the age of onset of use and lead to more problematic use of cannabis and other recreational drugs via vaping devices. Our study demonstrates a significant number (9.4%) of respondent's currently use an electronic vaping device for recreational drug administration with 6.2% reporting lifetime cannabis vaping use. Additionally there was high overall reported lifetime vaping across all drug classes. Our data suggests a higher than national prevalence of cigarette smoking, e-cigarette smoking and lifetime recreational drug use which may skew these results. However, this preliminary small survey does demonstrate a broad trend in the use of electronic vaping devices for recreational drug administration and should serve as a base for further larger scale studies to accurately describe its epidemiology to help inform the appropriate treatment and primary prevention strategies for this emerging issue.
